#United States #Prostate Cancer #Francis Medical #Maple Grove #Vanquish System

Francis Medical's Strategic Growth Through Financing

On November 10, 2026, Francis Medical, Inc., a Minnesota-based medical device company, announced a strategic financing initiative led by Johnson & Johnson's venture capital division, Johnson & Johnson Innovation (JJDC). This funding marks a significant step forward in the company's ongoing mission to develop minimally invasive therapies specifically targeting urological cancers.

Investment Milestone and Goals

The agreement will provide Francis Medical with the capital necessary to enhance its commercial infrastructure, improve market access initiatives, and strengthen physician training, ultimately leading to broader adoption of their flagship product, the Vanquish System. This strategic move is vital as the company prepares to submit for Premarket Approval (PMA) to the FDA, aimed at addressing clinically localized prostate cancer.

Expressing the significance of this financing, Mike Kujak, President and CEO of Francis Medical, stated, "This is a pivotal moment in our evolution as we prepare to broaden our presence in the U.S. market. With JJDC's support, we can expedite the growth of our commercial organization, enabling more physicians to access this innovative technology." He emphasized the company’s commitment to advancing clinical evidence and regulatory milestones that will support their efforts in managing prostate cancer.

Innovations in Prostate Cancer Treatment

The Vanquish System is a cutting-edge transurethral device that utilizes ultrasound and electromagnetically guided thermotherapy to ablate specific prostate tissues through the application of convective water vapor energy. This system has been shown to target thermal energy delivery precisely within the prostate, aiming to ablate tissue while minimizing potential negative effects on nearby structures, which are crucial for preserving urinary and sexual functions.

In November 2025, the Vanquish System secured 510(k) clearance from the FDA based on positive interim results from the ongoing pivotal study, VAPOR 2. This study involves a multicenter, single-arm trial, with 235 patients enrolled across 26 locations in the U.S., focusing on those diagnosed with intermediate-risk localized prostate cancer.

Positive Clinical Outcomes

Recent findings from the VAPOR 2 study, published in The Journal of Urology, reveal promising results—91% of participating patients exhibited no clinically significant MRI-visible cancer in the treated area after undergoing just one procedure. Furthermore, there were no reports of serious adverse events associated with the device, and patient satisfaction levels were high; 93% reported being satisfied or extremely satisfied with the procedure.

"Francis Medical was founded on the principle that men facing prostate cancer deserve treatment options that do not compromise their quality of life," remarked Michael Hoey, Founder and Chief Technology Officer of the company. He believes that behind every diagnosis lies a story worth protecting and that the Vanquish System embodies this commitment. The recent funding will facilitate further access to this technology, driving Francis Medical closer toward improving prostate cancer care.

Piper Sandler served as the exclusive financial advisor for this financing transaction, underlining the strategic importance of this investment for the future growth of Francis Medical.

Conclusion

In conclusion, with the backing of Johnson & Johnson, Francis Medical is poised to enhance its impact in the treatment of prostate cancer. This financing not only supports the company’s innovative technology but also confirms its long-standing commitment to improving the quality of life for patients. The upcoming PMA submission will be crucial in determining the Vanquish System’s future role in clinical practice, potentially ushering significant improvements in prostate cancer management and patient outcomes.